Benjamin M. Ellingson
YOU?
Author Swipe
View article: Focused Ultrasound in Brain Tumors: Mechanisms, Imaging Guidance, and Emerging Clinical Applications
Focused Ultrasound in Brain Tumors: Mechanisms, Imaging Guidance, and Emerging Clinical Applications Open
Focused ultrasound (FUS) is an emerging therapeutic and diagnostic technology in neuro-oncology, offering new strategies for molecular diagnosis, drug delivery, and tumor ablation across a range of brain tumors, including glioblastoma (GBM…
View article: NCOG-37. Outcomes from online education focused on novel targeted therapies for IDH-mutant gliomas
NCOG-37. Outcomes from online education focused on novel targeted therapies for IDH-mutant gliomas Open
BACKGROUND The identification of IDH mutations has transformed glioma classification and opened new therapeutic avenues in neuro-oncology. This study evaluated the impact of an online continuing medical education (CME) activity on clinicia…
View article: IMG-99. Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial
IMG-99. Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial Open
TGR shows emerging utility as a quantitative measure for assessing treatment efficacy in glioma. We evaluated three distinct TGR models using volumetric data from patients with mIDH1/2 diffuse glioma from the Phase 3 INDIGO trial (NCT04164…
View article: IMG-43. Non-Invasive Prediction of Malignant Transformation in Grade 2 IDH-Mutant Gliomas Using Radiomics and Machine Learning
IMG-43. Non-Invasive Prediction of Malignant Transformation in Grade 2 IDH-Mutant Gliomas Using Radiomics and Machine Learning Open
Grade 2 IDH mutant gliomas are known to undergo malignant transformation (MT). Early prediction of this transformation remains a significant clinical challenge. Radiomics, the extraction of high-dimensional imaging features, has emerged as…
View article: IMG-64. Baseline imaging metrics stratifying progression-free survival and overall survival in primary central nervous system lymphoma treated with high-dose methotrexate
IMG-64. Baseline imaging metrics stratifying progression-free survival and overall survival in primary central nervous system lymphoma treated with high-dose methotrexate Open
BACKGROUND First-line therapy for primary central nervous system lymphoma (PCNSL) typically incorporates high-dose methotrexate. Despite high response rates (40-70%), a subset of patients (20-40%) progress during or after induction therapy…
View article: IMG-89. Volumetric (3D) compared with traditional bidirectional (2D) assessment in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial
IMG-89. Volumetric (3D) compared with traditional bidirectional (2D) assessment in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial Open
While Response Assessment in Neuro-oncology (RANO) criteria remain the standard for brain tumor evaluation, 3D volumetric measurements may provide more accurate tumor assessments. We compared 2D RANO per blinded independent review committe…
View article: IMG-116. Diffusion-Relaxation Correlation Spectroscopic Imaging Differentiates Brain Tumor Progression and Treatment Effects: a Pilot Study
IMG-116. Diffusion-Relaxation Correlation Spectroscopic Imaging Differentiates Brain Tumor Progression and Treatment Effects: a Pilot Study Open
INTRODUCTION Differentiating treatment effects (TxE), including cases with radiation necrosis and/or with gliosis and hyalinized vessels on histopathology, from tumor progression in irradiated brain tumors remains a clinical challenge due …
View article: TIP-10. Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
TIP-10. Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma Open
BACKGROUND GBM AGILE (Glioblastoma Adaptive, Global, Innovative Learning Environment) is a multi-arm, international, seamless Phase 2/3 response adaptive randomization (RAR) platform trial designed to efficiently identify investigational t…
View article: IMG-68. Corticosteroid-induced contrast-enhancing volume shrinkage and apparent diffusion coefficient reduction in glioblastoma MRI
IMG-68. Corticosteroid-induced contrast-enhancing volume shrinkage and apparent diffusion coefficient reduction in glioblastoma MRI Open
BACKGROUND Corticosteroids, which are commonly used in the clinical management of glioblastoma, are known to impact the radiographic interpretation of glioblastoma. In particular, corticosteroids can induce an apparent reduction in contras…
View article: CTIM-12. DUAL IMMUNE CHECKPOINT BLOCKADE FOR SURGICALLY ACCESSIBLE RECURRENT GLIOBLASTOMA: CLINICAL AND MOLECULAR OUTCOMES
CTIM-12. DUAL IMMUNE CHECKPOINT BLOCKADE FOR SURGICALLY ACCESSIBLE RECURRENT GLIOBLASTOMA: CLINICAL AND MOLECULAR OUTCOMES Open
Our previous study of neoadjuvant PD-1 immune checkpoint blockade (ICB) in surgically-accessible recurrent glioblastoma suggested that single-agent PD-1 blockade induced adaptive immune responses that may have paradoxically inhibited funct…
View article: EXTH-02. GliomaPDOX – A direct brain-to-brain glioma xenograft library for drug discovery and development
EXTH-02. GliomaPDOX – A direct brain-to-brain glioma xenograft library for drug discovery and development Open
Cancer drug discovery and development rely on preclinical models that accurately reflect the molecular and functional characteristics of human tumors, while accounting for in vivo factors that influence drug efficacy, such as pharmacokinet…
View article: Contralateral neurofluid dynamics predict survival in IDH wild-type glioblastoma: A DTI-ALPS and free water imaging study
Contralateral neurofluid dynamics predict survival in IDH wild-type glioblastoma: A DTI-ALPS and free water imaging study Open
Background Glioblastoma (GBM) may disrupt glymphatic function and neurofluid dynamics locally and in distant brain regions. However, the prognostic relevance of such alterations remains unclear. We investigated whether diffusion tensor ima…
View article: OS09.4.A EARLY TUMOR VOLUME CHANGES PREDICT CLINICAL OUTCOMES IN MIDH1/2 GLIOMA: POST-HOC RESULTS FROM THE PHASE 3 INDIGO TRIAL
OS09.4.A EARLY TUMOR VOLUME CHANGES PREDICT CLINICAL OUTCOMES IN MIDH1/2 GLIOMA: POST-HOC RESULTS FROM THE PHASE 3 INDIGO TRIAL Open
BACKGROUND In the Phase 3 INDIGO trial (NCT04164901), vorasidenib, an oral, brain-penetrant, dual inhibitor of mutated isocitrate dehydrogenase 1/2 (mIDH1/2), improved progression-free survival (PFS) versus placebo in patients with mIDH1/2…
View article: GFAP Degradation in TBI: Linking Novel Modified Products to Astrocyte Pathology and Patient Outcome
GFAP Degradation in TBI: Linking Novel Modified Products to Astrocyte Pathology and Patient Outcome Open
Glial fibrillary acidic protein (GFAP) is an important clinical biomarker of traumatic brain injury (TBI), yet understanding the nature, timing, and impact of its degraded and modified products is needed for clinical utility. We report dis…
View article: NIRA-04 DIFFERENTIATION OF BRAIN TUMOR PROGRESSION AND TREATMENT EFFECT USING DIFFUSION-RELAXATION CORRELATION SPECTROSCOPIC IMAGING
NIRA-04 DIFFERENTIATION OF BRAIN TUMOR PROGRESSION AND TREATMENT EFFECT USING DIFFUSION-RELAXATION CORRELATION SPECTROSCOPIC IMAGING Open
Differentiating treatment effects (TxE) from tumor progression in glioma and metastatic brain tumors is challenging due to their similar clinical presentations and conventional MRI characteristics. Scenarios with mixed pathology further co…
View article: Diffusion and contrast-enhancement MRI phenotypes associated with immune checkpoint inhibitor exposure and with immune cell infiltration in brain metastases
Diffusion and contrast-enhancement MRI phenotypes associated with immune checkpoint inhibitor exposure and with immune cell infiltration in brain metastases Open
Background MRI-derived apparent diffusion coefficient (ADC) and contrast-enhancement (CE) may represent noninvasive biomarkers to evaluate microstructural tissue changes and histopathological immune cell infiltration induced by immune chec…
View article: Normalization of the percentage of signal recovery derived from dynamic susceptibility contrast perfusion MRI in brain tumors
Normalization of the percentage of signal recovery derived from dynamic susceptibility contrast perfusion MRI in brain tumors Open
The universalizability of the metric percentage of signal recovery (PSR) derived from dynamic susceptibility contrast (DSC) perfusion MRI is limited by its dependency of acquisition parameters. In this technical assessment, we tested diffe…
View article: Table S15 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S15 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
GSEA analysis of genes with significantly increased H3K27me3 in ONC201-treated versus untreated patients.
View article: Table S3 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S3 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
Individual cases from historical control datasets.
View article: Table S2 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S2 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
Individual patients with H3K27M-mutant DMG treated with ONC201.
View article: Table S11 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S11 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
Volcano plot of differentially expressed genes in DIPG007 cells treated with ONC201 versus vehicle.
View article: Table S13 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S13 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
GSEA analysis of genes with significantly lower chromatin accessibility at promoters and enhancers and reduced gene expression in DIPG007 cells treated with ONC201 versus vehicle.
View article: Table S12 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S12 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
Results of pathway impact analysis after performing integrated RNA-seq and metabolomics analysis using MetaboAnalyst.